title: IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
abstract: Human immunodeficiency virus (HIV)-infected persons are less likely than are noninfected persons to respond to vaccination with pneumococcal polysaccharides (PPS). Among those who respond, however, similar IgG levels may be achieved. HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-level responders (IgG > or = 1 microgram/mL for > or = 3 of 5 PPS [high] or for < or = 1 PPS [low]). One and 2 years after immunization, geometric mean IgG levels and the percentages of subjects with IgG levels > or = 1 microgram/mL were similar for HIV-infected and for healthy high-level responders (controls) for all PPS except for serotype 8. Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses. Responsiveness of HIV-infected white patients was significantly associated with the Km(1)- negative allotype. These findings support current general recommended guidelines for administering pneumococcal vaccine to HIV-infected persons. Nonresponders will not benefit from revaccination.
authors.affiliation: Medical Service, VA Medical Center, Houston, TX 77030, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Rodriguez-Barradas
authors.forename: J E
authors.initials: JE
authors.lastname: Groover
authors.forename: C E
authors.initials: CE
authors.lastname: Lacke
authors.forename: D W
authors.initials: DW
authors.lastname: Gump
authors.forename: C J
authors.initials: CJ
authors.lastname: Lahart
authors.forename: J P
authors.initials: JP
authors.lastname: Pandey
authors.forename: D M
authors.initials: DM
authors.lastname: Musher
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial; D016667:Bacterial Capsules / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007126:Immunoglobulin Allotypes / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D007126:Immunoglobulin Allotypes; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines